0001437749-22-029969.txt : 20221230 0001437749-22-029969.hdr.sgml : 20221230 20221230202125 ACCESSION NUMBER: 0001437749-22-029969 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221216 FILED AS OF DATE: 20221230 DATE AS OF CHANGE: 20221230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Phillip E CENTRAL INDEX KEY: 0001959565 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 221503049 MAIL ADDRESS: STREET 1: C/O VAXART, INC. STREET 2: 170 HARBOR WAY, STE. 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 4 1 rdgdoc.xml FORM 4 X0306 4 2022-12-16 0000072444 Vaxart, Inc. VXRT 0001959565 Lee Phillip E C/O VAXART, INC. 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 Chief Financial Officer Common Stock 2022-12-16 4 A 0 68750 0 A 68750 D Stock Option (Right to Buy) 1.06 2022-12-16 4 A 0 412500 0 A 2032-12-15 Common Stock 412500 412500 D Grant of shares upon vesting of restricted stock units ("RSUs"). The RSUs vest as to 25% of the shares underlying the award on each anniversary of December 15, 2022 (the "Start Date"), so that the RSUs would be fully vested on the fourth anniversary of the Start Date. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on December 15,2023, the first anniversary of the Start Date, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on December 16, 2026. /s/ Edward Berg, Attorney-in-Fact for W. Mark Watson 2022-12-28